Adenosine receptor subtype modulators: Insight into molecular mechanisms and their therapeutic application

Area of Science:

• Pharmacology and Molecular Biology
• Cardiovascular and Neurological Sciences
• Immunology and Oncology

Background:

• Four adenosine receptor (AR) subtypes (A1, A2A, A2B, A3) modulate critical physiological and pathological processes.
• ARs are implicated in neuroprotection, inflammation, cardiac function, and cancer development.
• Specific AR subtypes show therapeutic promise for conditions including Parkinson's disease, cancer, asthma, diabetes, and autoimmune disorders.

Purpose of the Study:

• To review the molecular mechanisms and tissue-specific roles of adenosine receptor subtypes.
• To assess the translational progress of AR-targeted therapies.
• To advocate for innovation in developing selective AR ligands with improved clinical outcomes.

Main Methods:

• Review of recent scientific literature on adenosine receptor subtypes and their therapeutic applications.
• Analysis of molecular mechanisms, physiological roles, and clinical trial data.
• Examination of challenges and advancements in AR-specific drug development.

Main Results:

• AR-specific agonists and antagonists are being investigated for heart failure, ischemia, neurodegenerative diseases, and inflammatory disorders.
• Current AR therapies face challenges including side effects, low receptor selectivity, and species-specific drug responses.
• Advances include selective drugs for glaucoma, asthma, oncology, and new strategies for neurodegenerative diseases and chronic inflammation.

Conclusions:

• Targeting adenosine receptors offers significant therapeutic potential for a wide range of diseases.
• Overcoming challenges related to selectivity and side effects is crucial for realizing the full clinical benefit of AR therapies.
• Continued innovation in developing receptor-specific ligands is essential for transforming treatment landscapes.